IN-VITRO AND IN-VIVO ACTIVITY OF TOPOTECAN AGAINST HUMAN B-LINEAGE ACUTE LYMPHOBLASTIC-LEUKEMIA CELLS

被引:53
|
作者
UCKUN, FM
STEWART, CF
REAMAN, G
CHELSTROM, LM
JIN, JH
CHANDANLANGLIE, M
WADDICK, KG
WHITE, J
EVANS, WE
机构
[1] UNIV MINNESOTA, DEPT PHARMACOL, MINNEAPOLIS, MN 55455 USA
[2] UNIV MINNESOTA, DEPT PEDIAT, MINNEAPOLIS, MN 55455 USA
[3] UNIV MINNESOTA, DEPT LAB MED PATHOL, MINNEAPOLIS, MN 55455 USA
[4] ST JUDE CHILDRENS RES HOSP, DEPT PHARMACEUT, MEMPHIS, TN 38105 USA
[5] CHILDRENS NATL MED CTR, DEPT HEMATOL ONCOL, WASHINGTON, DC 20010 USA
[6] CHILDRENS CANC RES GRP, ARCADIA, CA USA
关键词
D O I
10.1182/blood.V85.10.2817.bloodjournal85102817
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Topotecan [(S)-9-dimethylaminomethyl-10-hydroxycamptothecin hydrochloride; SK&F 104864-A, NSC 609699], a water soluble semisynthetic analogue of the alkaloid camptothecin, is a potent topoisomerase I inhibitor. Here we show that topotecan stabilizes topoisomerase I/DNA cleavable complexes in radiation-resistant human B-lineage acute lymphoblastic leukemia (ALL) cells, causes rapid apoptotic cell death despite high-level expression of bcl-2 protein, and inhibits ALL cell in vitro clonogenic growth in a dose-depen-dent fash ion. Furthermore, topotecan elicited potent antileukemic activity in three different severe combined immunodeficiency (SCID) mouse models of human poor prognosis ALL and markedly improved event-free survival of SCID mice challenged with otherwise fatal doses of human leukemia cells at systemic drug exposure levels that can be easily achieved in children with leukemia. (C) 1995 by The American Society of Hematology.
引用
收藏
页码:2817 / 2828
页数:12
相关论文
共 50 条
  • [1] THERMAL SENSITIVITY AND THERMAL TOLERANCE OF HUMAN B-LINEAGE ACUTE LYMPHOBLASTIC-LEUKEMIA (ALL) CELLS
    MIN, WS
    SONG, CW
    UCKUN, FM
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 18 (01): : 147 - 153
  • [2] CLONAL INSTABILITY IN EARLY B-LINEAGE ACUTE LYMPHOBLASTIC-LEUKEMIA
    POTTER, MN
    STEWARD, CG
    OAKHILL, A
    BLOOD, 1992, 80 (06) : 1631 - 1631
  • [3] ASYNCHRONOUS ANTIGEN EXPRESSION IN B-LINEAGE ACUTE LYMPHOBLASTIC-LEUKEMIA
    HURWITZ, CA
    LOKEN, MR
    GRAHAM, ML
    KARP, JE
    BOROWITZ, MJ
    PULLEN, DJ
    CIVIN, CI
    BLOOD, 1988, 72 (01) : 299 - 307
  • [4] INVIVO AND INVITRO EXPRESSION OF MYELOID ANTIGENS ON B-LINEAGE ACUTE LYMPHOBLASTIC-LEUKEMIA CELLS
    HARA, J
    KAWAHA, K
    YUMURAYAGI, K
    KURAHASHI, H
    TAWA, A
    ISHIHARA, S
    INOUE, M
    MURAYAMA, N
    OKADA, S
    LEUKEMIA, 1991, 5 (01) : 19 - 25
  • [5] INVERSION 14Q IN ACUTE LYMPHOBLASTIC-LEUKEMIA OF B-LINEAGE
    WONG, KF
    KWONG, YL
    WONG, TK
    CANCER GENETICS AND CYTOGENETICS, 1995, 80 (01) : 72 - 74
  • [6] MOLECULAR MECHANISMS OF CLONAL EVOLUTION IN B-LINEAGE ACUTE LYMPHOBLASTIC-LEUKEMIA
    CHOI, Y
    DU, TL
    WARD, P
    OVERTURF, P
    BRECHER, M
    BALLOW, M
    GREENBERG, SJ
    CLINICAL RESEARCH, 1994, 42 (02): : A125 - A125
  • [7] IN-VITRO LEUKEMIC-CELL GROWTH ON STROMA PREDICTS OUTCOME IN CHILDHOOD B-LINEAGE ACUTE LYMPHOBLASTIC-LEUKEMIA (ALL)
    KUMAGAI, M
    MANABE, A
    BEHM, FG
    RAIMONDI, SC
    HANCOCK, M
    CRIST, WM
    MAHMOUD, H
    PUI, CH
    CAMPANA, D
    BLOOD, 1994, 84 (10) : A516 - A516
  • [8] GRAFT-VERSUS-LEUKEMIA EFFECT IN T-LINEAGE AND B-LINEAGE ACUTE LYMPHOBLASTIC-LEUKEMIA (ALL)
    PASSWEG, JR
    BARRETT, AJ
    ROWLINGS, PA
    ZHANG, MJ
    HOROWITZ, MM
    EXPERIMENTAL HEMATOLOGY, 1995, 23 (08) : 857 - 857
  • [9] AN ANTI-CD72 IMMUNOTOXIN AGAINST THERAPY-REFRACTORY B-LINEAGE ACUTE LYMPHOBLASTIC-LEUKEMIA
    MYERS, DE
    UCKUN, FM
    LEUKEMIA & LYMPHOMA, 1995, 18 (1-2) : 119 - 122
  • [10] QUESTION OF STEMLINES IN HUMAN ACUTE LEUKEMIA - COMPARISON OF CELLS ISOLATED IN-VITRO AND IN-VIVO FROM A PATIENT WITH ACUTE LYMPHOBLASTIC LEUKEMIA
    ADAMS, RA
    POTHIER, L
    FLOWERS, A
    LAZARUS, H
    FARBER, S
    FOLEY, GE
    EXPERIMENTAL CELL RESEARCH, 1970, 62 (01) : 5 - &